12:00 AM
Jun 24, 2013
 |  BioCentury  |  Emerging Company Profile

Cristal: Tunable nanoparticles

Cristal using tunable polymeric nanoparticles to improve therapeutic profiles

Cristal Therapeutics aims to improve the therapeutic profile of drugs by entrapping them within biodegradable polymeric nanoparticles. While the company's CriPec platform has several characteristics in common with other polymer-based nanoparticle carriers, it may be better able to increase efficacy and safety.

The platform uses thermosensitive polymers that self-assemble into micelles when the temperature is raised above a critical level. During the process, sections of the polymers that make up the micelle core polymerize and form crosslinks with one another, thus stabilizing the micelle to form the CriPec nanoparticle and preventing its premature dissociation upon administration.

Separately, therapeutic molecules are covalently conjugated to a linker molecule. The drug-linker conjugate then is encapsulated within the nanoparticle during self-assembly and covalently linked to its core.

Cristal can entrap a range of therapeutic small molecules and peptides within CriPec nanoparticles.

Cristal's closest competitor is Bind Therapeutics Inc., which is developing Accurin nanoparticles that encapsulate therapeutic payloads within its polymeric matrix (see BioCentury, July 21, 2008).


Read the full 810 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >